1
/
of
0
FDA Drug/Biologics Approval BLA 125085 S-331, BEVACIZUMAB
FDA Drug/Biologics Approval BLA 125085 S-331, BEVACIZUMAB
Regular price
$149.00 USD
Regular price
Sale price
$149.00 USD
Unit price
/
per
BLA 125085 S-331
Company: GENENTECH
Drug Name: AVASTIN
Active Ingredients: BEVACIZUMAB
Strength: 400MG
Dosage Form/Route: VIAL; INTRAVENOUS
Action Date: 02/26/2004
Marketing Status: Prescription
Submission Classification: ORIG-1
Company: GENENTECH
Drug Name: AVASTIN
Active Ingredients: BEVACIZUMAB
Strength: 400MG
Dosage Form/Route: VIAL; INTRAVENOUS
Action Date: 02/26/2004
Marketing Status: Prescription
Submission Classification: ORIG-1
Couldn't load pickup availability
- Status: Pending Fast-Track Request
- Delivery: Approximately 1 to 2 weeks
NOTE: This document is not currently in our library. Upon purchase, we will request the document from the FDA FOIA office. Learn more about Fast-Track Requests here.
View full details